Axsome Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.
Key statistics
Against its peers
Compare in full ›| 19X.F | ACAD | PRAX | ATAI | SANION.ST | HRMY | |
|---|---|---|---|---|---|---|
| Market cap | 6.38B | 2.96B | 8.40B | — | 1.55B | 1.91B |
| P/E (TTM) | — | 8.1 | — | — | 8.7 | 10.8 |
| Forward P/E | -31.7 | 15.8 | -30.6 | — | — | 5.4 |
| Price/book | 68.0 | 2.1 | 6.7 | — | 2.8 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −5.78% | −25.34% | +83.10% | — | −27.76% | −3.88% |
| Today | −0.65% | −2.73% | −3.37% | 0.00% | +0.36% | −1.18% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 19X.F news ›Axsome Therapeutics, Inc. (AXSM) Presents at UBS Global Biopharma Conference 2026 Transcript
Transcripts Axsome Therapeutics, Inc. (AXSM) UBS Global Biopharma Conference 2026 November 16, 2026 6:20 AM EST Mark Jacobson - Chief Operating Officer Nick Pizzie - Chief Financial Officer Ashwani Verma - UBS Investment Bank, Research…
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
Axsome's revenue has climbed about 54% while Moderna's net losses run deep, but a steep valuation gap may tip the scales for patient investors. By Brendan Coffey – Updated Nov 14, 2026 at 11:12AM EST Key Points Axsome Therapeutics is…
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Up 5.9% – What’s Next?
Posted by Tristan Rich on Nov 12th, 2026 Share on Twitter Share on Facebook Share on LinkedIn Share on Stocktwits Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report)’s share price was up 5.9% on Tuesday. The company tr
Axsome Therapeutics, Inc. (AXSM) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Axsome Therapeutics, Inc. (AXSM) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 11:30 AM EST Mark Jacobson - Chief Operating OfficerNick Pizzie - Chief Financial Officer Yatin Suneja - Guggenheim Securities, LLC,…
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Published on 11/03/2026 at 07:00 am EST NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today…
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI® 3Q 2026 net product revenue of $48.2 million,…
Axsome Therapeutics (NASDAQ:AXSM) Stock Gets Price Target Reduction from Royal Bank Of Canada
Posted by Danessa Lincoln on Nov 6th, 2026 Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price decreased by Royal Bank Of Canada from $295.00 to $273.00 in a research report sent to investors on Tuesday,Benzinga reports.…
Axsome Therapeutics: Sentiment Meets Reality After Q3 (Rating Upgrade)
Axsome Therapeutics is upgraded to Hold as valuation resets after ADA approval. Read the latest analysis on AXSM stock here. - Axsome Therapeutics is upgraded to 'Hold' as its valuation now better reflects commercial realities post-ADA…
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) had its price target boosted by stock analysts at Morgan Stanley from $247.00 to $249.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an "equal…
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
Posted by Sarita Garza on Nov 3rd, 2026 Axsome Therapeutics (NASDAQ:AXSM) reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer’s…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com6
- seekingalpha.com6
- themarketsdaily.com5
- fool.com4
- markets.businessinsider.com4
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 30 articles, not a forecast.